Philadelphia‐positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID‐19 pandemic: a Campus ALL study
- 14 June 2020
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 190 (1), E3-E5
- https://doi.org/10.1111/bjh.16758
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Coronaviruses and Immunosuppressed Patients: The Facts During the Third EpidemicLiver Transplantation, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- COVID-19: the new challenge for rheumatologistsClinical and Experimental Rheumatology, 2020
- COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?Clinical and Experimental Rheumatology, 2020
- Potentially highly potent drugs for 2019-nCoVPublished by Cold Spring Harbor Laboratory ,2020
- Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba TrialBlood, 2019
- Management of adult Ph-positive acute lymphoblastic leukemiaHematology-American Society Hematology Education Program, 2015
- Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohortsHaematologica, 2013
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood, 2011
- Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocolBlood, 2007